Selected Refereed Journal Articles | Phase I Biomarker Laboratory

Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Venook AP, Baez-Diaz L, Lenz HJ, O’Neil BH, Innocenti F, Meyerhardt JA, O’Reilly EM, Owzar K, Hurwitz HI (2022) Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-21-2389

Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ (2022) Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-21-2386

Liu Y, Lyu J, Burdett KB, Sibley AB, Hatch AJ, Starr MD, Brady JC, Hammond K, Marmorino F, Rossini D, Goldberg RM, Falcone A, Cremolini C, Owzar K, Ivanova A, Moore DT, Lee MS, Sanoff HK, Innocenti F, Nixon AB (2020) Prognostic and predictive biomarkers in patients with metastatic colorectal cancer receiving regorafenib. Mol Cancer Ther. Oct;19(10): 2146-2154 https://mct.aacrjournals.org/content/19/10/2146

Lampert EJ, Zimmer A, Padget M, Mathews AC, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. (2020) Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 26(16):4268-4279. https://clincancerres.aacrjournals.org/content/26/16/4268

Second AA, Burdett KB, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lances HA, Hurwitz HI, Mannel RS, Tewari KS, O’Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. (2020) Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: results from GOG-0218. Clin Cancer Res. 26(6):1288-1296. https://clincancerres.aacrjournals.org/content/26/6/1288

Choueiri, TK, Michaelson, MD, Posadas, EM, Sonpavde, GP, McDermott, DF, Nixon, AB, Liu, Y, Yuan, Z, Seon, BK, Walsh, M, Jivani, MA, Adams, BJ, and Theuer, CP. (2019) An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.” The Oncologist 24, 2: 202-210. https://www.ncbi.nlm.nih.gov/pubmed/30190302

Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB (2018) Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody TRC105. Mol Cancer Ther. Oct;17(10): 2248-2256 http://mct.aacrjournals.org/content/17/10/2248

Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I. (2018) Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. https://www.futuremedicine.com/doi/10.2217/fon-2018-0051

Seligmann JF, Hatch AJ, Richman SD, Elliott F, Jacobs B, Brown S, Hurwitz H, Barrett JH, Quirke P, Nixon AB, Seymour MT. (2017) Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncol. 2018 Apr 1;4(4):564-568. https://jamanetwork.com/journals/jamaoncology/fullarticle/2659372

Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB (2016)Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med. Sep;5(9):2249-2260 https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.806

Kim, H.L., Halabi, S., Ping, L., Mayhew, G., Simko, J., Nixon, A.B., Small, E.J., Rini B.I., Morris, M.I., Taplin, M.E., George, D.G. (2015) A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine Nov; 2(11):1814-1820. https://www.sciencedirect.com/science/article/pii/S2352396415301328?via%3Dihub

Hatch AJ, Clark JM, Nixon AB,Hurwitz HI. (2015)Identifying blood-based protein biomarkers for anti-angiogenic agents in the clinic: A decade of progress. Cancer Journal. Jul-Aug;21(4):322-326. https://www.ncbi.nlm.nih.gov/pubmed/?term=Hatch+aj+and+clark+jm+2015

Jia J, Dellinger A, Bulusu A, Weiss E, Rushing C, Li H, Howard L, Kaplan N, Pang H, Hurwitz H, Nixon AB. (2015) Direct Evidence of Target Inhibition with anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clin Cancer Res. Aug;21(15):3442-3452. http://clincancerres.aacrjournals.org/content/21/15/3442.long

Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H, Honeycutt W, Amara A, Altomare I, Uronis HE, Hurwitz HI, Nixon AB. (2015) Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. Mol Cancer Ther. Apr;14(4):1048-56. http://mct.aacrjournals.org/content/14/4/1048.long

Cushman S, Jiang C, Hatch A, Shterev I, Sibley A, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB. (2015) Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance). Clin Cancer Res. Mar 1;21(5):1078-1086. http://clincancerres.aacrjournals.org/content/21/5/1078.long

Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB. (2014) Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs. Oct; 32(5): 851-859. https://link.springer.com/article/10.1007%2Fs10637-014-0129-y

Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC. (2014) Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion. Mol Biol Cell. Aug 15;25(16):2320-32. https://www.molbiolcell.org/doi/full/10.1091/mbc.E13-09-0524?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&

Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB. (2014) Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med. Jun; 3(3): 580-591. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.207

Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303 (Alliance). Clin Cancer Res. 19(24):6957-6966. http://clincancerres.aacrjournals.org/content/19/24/6957.long

Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI,Nixon AB. (2013) Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med. 2(2):234-242. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.71

Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC. (2013) Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. Clin. Invest. 123(9):3925-40. https://www.jci.org/articles/view/65745

Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB. (2013)Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer Drugs. 24(3):237-250. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828660/

Facemire, C.S., Nixon, A.B., Griffiths, R., Hurwitz, H. Coffman, T.M. (2009) Vascular endothelial growth factor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 54:652-8. https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.109.129973?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H.I., Dev, I., Nixon, A.B., Lyerly, H.K., Clay, T., Morse, M.A. (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57:1152-24. https://link.springer.com/article/10.1007%2Fs00262-007-0441-x